Aims-To determine the sensitivity of the partial rescreening method of rapid review for internal quality control of cervical cytology; to determine which staff members are most suited to undertake it; and to investigate the cell patterns of false negative smears previously detected by the method. Methods-As a prospective study 9517 cervical smears were partially screened by four cytotechnologists using the 'step' method prior to conventional screening and the results compared with the final report. As a retrospective study 62 false negative smears that had been identified by the method over four years were reviewed. Results-A detection rate for dyskaryosis of 86% (range 82-91%) was achieved.
Sixteen abnormal smears were missed on conventional screening that had been detected by prescreening. Review of the 62 false negatives revealed three patterns: (1) scanty abnormal cells; (2) abundant dyskaryotic cells presenting as "microbiopsies"; and (3) abundant, readily recognisable abnormal cells. Conclusions-Partial rescreening enables the detection of errors due to both fatigue and misinterpretation. In this laboratory the method has, together with targeted full rescreening, reduced the false negative report rate from 5.0% to 0.4%. For laboratories using a rapid review method to reduce false negative reports, a prescreening trial is recommended in order (1) to select the most effective review method and the staff most suited to undertake it; and (2) to determine the laboratory's sensitivity with the method, as this is required for accurate estimation of the false negative rate. (3 Clin Pathol 1996 ;49:587-591) Keywords : partial rescreening, rapid review, cervical screening, internal quality control.
intraepithelial neoplasia is believed to be less than that for invasive carcinoma, but in some laboratories it may be as high as 20%. [3] [4] [5] In the United States there has been much media attention devoted to screening errors6 7 and in Britain occasional reports appear in the press. Traditional methods of internal quality control, such as targeted rescreening of previously abnormal and symptomatic cases and 10% random rescreening of negative smears, can only make a limited contribution to reducing the number of false negative reports. This is because only a small proportion of negative smears are rescreened. Recently, partial rescreening8 9 and rapid screening" 01 have been proposed as an improved alternative to 10% random rescreening as a method of internal quality control. The principle of partial rescreening, as proposed by one of us, is that all negative and inadequate smears are subjected to a quick review after conventional screening but prior to issue of the report. Partial rescreening and rapid screening are now known collectively by the umbrella term rapid review and are recommended to NHS laboratories by the Scottish Office Working Party on Internal Quality Control for Cervical Cytology Laboratories12 and a working party set up by the Royal College of Pathologists, the British Society for Clinical Cytology and the NHS Cervical Screening Programme.13
As this procedure is adopted it is important that each laboratory determines which method is to be used and which of its staff members are best qualified to undertake it, in order to maximise the portion of false negatives that are detected. The aim of this study was to investigate prospectively the performance of four cytotechnologists in carrying out partial rescreening and examine the factors that may influence ability with the method. In addition, we examined retrospectively 62 of the false negative smears that had been detected by rapid review between 1991 and 1994 to determine whether there were particular smear patterns that were habitually missed on conventional screening. Accepted for publication 21 March 1996 According to Koss one of the tragedies of cervical cytology is the high incidence of false negative smear reports issued by cytology laboratories.' In a British study, 65% of cervical smears reported as negative, taken from women who later developed invasive disease, were found to contain dyskaryotic cells on review.2 The screening false negative rate for Methods All cervical smears submitted to the laboratory were partially screened before conventional screening (which we call rapid preview). Each cytotechnologist partially screened the entire workload until each had encountered around 100 abnormal smears. The number of slides prescreened each day by each participant rarely Over a four year period, the total number of smears screened and the total number of abnormals as detected by a combination of routine screening, rapid review (RR) and targeted full rescreening (TFR) is known from computer records. Abnormal smears represent 4.5% of the total. For the same period, the number of smears screened by each cytotechnologist is known from worksheets. For screener A-for example, this was 17 509. This figure multiplied by the abnormal rate of 4.5% gives the number of abnormals screener A would be expected to encounter-that is, 788 abnormals. The number of abnormal smears missed by screener A and detected by RR = 8 and by TFR = 4. Therefore the number of false negatives per 100 abnormals for screener A is 12/788 x 100 = 1.52.
Results
In total 9517 cervical and vault smears were prescreened by the four cytotechnologists, with each examining an average of 2380. The detection rate of abnormal smears for each individual is shown in abnormality, and more than 10 fields in six (50%) of 12 high grade smears.
Discussion
DETECTION OF ABNORMAL SMEARS BY PRESCREENING (TABLE 1) The screening false negative rate does not seem to correlate with success at rapid review. The false negative rates given in table 1 (column 3) for members of the laboratory represent all the false negatives detected by rapid review and targeted rescreening over a four year period (see Methods). One would perhaps expect a screener with a low false negative rate to achieve a high detection rate at rapid review. While this is true of cytotechnologist A, two others (B and C) performed equally yet have a notably different false negative rate (2.33% and 5.98%). Of 16 abnormal smears missed on conventional screening, 10 were detected by screener A on prescreening. Although this may suggest that screener A is more adroit at picking up errors it must be viewed in the context of who was carrying out the conventional screening during each participant's session. During screener A's trial, 70% of the screening was carried out by two screeners with false negative rates of 5.98 % and 7.7%, both of which rose to over 10% during this period. When screeners B and C (two and no false negatives detected) were carrying out the prescreening, the cytotechnologist with the 7.7% false negative rate was no longer screening and the bulk of the work was undertaken by a screener whose false negative rate is 1.52%.
Previous experience with the partial rescreening method of rapid review did not seem to influence success with the method. Screener A was the only participant with any significant experience with the method, having viewed over 50 000 slides, yet his detection rate was matched by D who has used the method on less than 1000. Screener B had experience of only a few 100 smears and C had none; both performed equally well. One might expect performance to improve as one gets used to the technique; however, detection rates throughout each participant's trial varied little, suggesting that there is no learning curve involved (fig 4) . This is not surprising as the only learning required is to master the technique of stepping, and this was achieved quickly by all participants.
Of interest is the higher detection rate achieved for mild dyskaryosis in this study (84%) compared with that quoted in the Scottish Office document"2 (between 50 and 72%).
The reasons for this difference are not clear; however, their method of rapid review is not stated.
INADEQUATE SMEARS (TABLE 2)
Rapid review has a contribution to make in checking for adequacy as in this study 52 (0.6%) reports were adjusted prior to issue in view of the prescreening findings. However, as lack of transformation zone material is no equacy" these results should be viewed in the false negative rate" for primary screening."' 15 light of this. We consider, however, that this can be As an additional experiment during the improved for overall laboratory performance course of this study, one of us determined how by the use of rapid review. There is not usually accurately a smear lacking indicators of prob-anything particularly 'difficult' about false able transformation zone sampling could be negative smears, they are mostly missed for the identified with the naked eye. The characteris-reasons outlined above. Robertson and Woodtic appearance was of cellular material distrib-end' found that only around 10% of their 92 uted in clumps and an absence of streaks and false negatives contained so few dyskaryotic swirls of mucus. Of 1062 smears, 96 were con-cells that "...there seemed little prospect of sidered in this category on microscopy and of detection by normal screening methods". these 70 (73%) had been correctly identified However, many of the false negatives reviewed macroscopically (there was a 2% overcall). in the present study contained very few abnorThis is a similar detection rate to partial mal cells, yet were detected by rapid review. We screening and we find it a useful exercise to have shown that use of rapid review enables the look for these features prior to screening.
detection of up to 87% of abnormal smears and it would therefore be reasonable to suggest RETROSPECTIVE REVIEW OF FALSE NEGATIVE that it enables the detection of up to 87% of SMEARS (FIGs 2 AND 3) false negative smears. This laboratory has, in False negative cytology smears due to labora-four years, detected 63 false negatives out of tory error may occur because the abnormal 2124 abnormal smears using rapid review, a cells are either not seen or because they are not detected false negative rate of 3.0%. This recognised as abnormal.'4 An obvious explana-figure must be adjusted for the sensitivity of tion for not seeing abnormal cells is that they our rapid review to give an estimated false are present in small numbers or appear in few negative rate. This sensitivity is 87% for the microscope fields. Of the low grade abnormali-cytotechnologist who carried out almost all of ties among the reviewed false negatives, most the rescreening so the correction factor is 100/ had 20 or fewer abnormal cells per slide. In 87. This gives an estimated false negative rate addition, the number of fields in which the cells of 3.4% (3.0 x 100/87). Add to this 1.6% for appeared was five or fewer in most cases. Con-the 34 errors detected by targeted full residering there may be 300 000 normal cells on screening (26 of 34 were rescreened because of each smear and around 300 fields (xlO objec-previous abnormal cytology and eight because tive), these errors are perhaps understandable. of symptoms) and the final false negative rate At the other end of the spectrum were eight for the laboratory becomes 5.0%, exactly the low grade abnormalities with over 100 cells per suggested benchmark. However, the errors slide appearing in many fields. The cells in found by rapid review (3.0%) and targeted these were readily recognised as abnormal by rescreening (1.6%) have been detected and the original screener when re-presented with amended prior to the report being issued so the slide. Therefore, as interpretation was not that while the laboratory's false negative rate the explanation, these errors must be due to a would be 5% if no quality control were carried major lapse in concentration. This may also out, the false negative rate for reports leaving explain why two of the slides showing high the laboratory is 0.4% [5.0 -(1.6 + 3.0)].
grade abnormalities containing over 100 cells Two recent quality assurance documents" " were missed. The other five, which included recommend monitoring the performance of three adenocarcinomas, were probably missed primary screening by calculating the sensitivity due to misinterpretation as they were not read-of screening with respect to the final report ily recognised as severe dyskaryosis on re-after rapid review, and sets an achievable range presentation. In these, the dyskaryotic cells of 85-95%. This laboratory's sensitivities using were present in "microbiopsies" consistent this criteria are 97% (2124/ [2124 + 63] x 100) for all abnormalities and 98.6% (847/ [847 + 12] x 100) for moderate dyskaryosis or worse. These figures are misleadingly flattering as they do not include false negatives detected by targeted full rescreening nor do they take into account the correction factor for the sensitivity of rapid review. If we include these our final sensitivities come down to 95% for all abnormalities and 97.3% for moderate dyskaryosis or worse. We believe false negatives detected by targeted full rescreening must be included when calculating the sensitivity of primary screening. We also believe inclusion of the correction factor is important, as without it a laboratory with a low sensitivity at rapid review may falsely achieve a screening sensitivity within the recommended achievable range.
The effectiveness of a quality assurance programme should result in a reduction in the proportion of false negative cervical smears in the laboratory's files. A recognised method of quality control is the review of previous negative smears from patients who present with an abnormal smear or biopsy specimen. If rapid review is successful at reducing the number of false negative smears one would expect to see a reduction in the proportion of false negatives among the reviewed slides. In this laboratory, review of previous negatives is carried out on all cases which present with a smear or biopsy specimen suggesting cervical intraepithelial neoplasia (CIN) 2, CIN 3 or carcinoma. Sixty six slides were reviewed that were screened originally in the years 1988, 1989 and 1990 and of these, 21 (32%) were found to contain dyskaryotic cells. The laboratory instituted rapid review at the beginning of 1991. Forty five slides screened since then have been reviewed for the reasons mentioned and of these, three (7%) were considered to be false negative. This is a significant reduction (p < 0.005, X2) in the proportion of false negative smears within this category and is evidence that the system is effective.
The PAPNET automated screening system (NSI, Suffern, NewYork, USA) has been proposed as a method of quality control for rescreening of smears after conventional screening and is said to detect abnormal cells in 97% of abnormal smears.'6 Our laboratory, with a false negative rate of 5% and about 500 abnormal smears per year should produce 25 false negatives annually. If we were to use the PAPNET as our sole method of internal quality control, the system should detect 24 of these (97% x 25). By using rapid review, we should detect 21 (87% x 25). The cost of detecting these three additional false negatives would be in excess of £100 000 on scanning charges and equipment rental alone. Moreover, the time required to check a smear using the PAPNET is at least double that of rapid review. As the latter was proposed as a replacement for 10% random rescreening, the extra burden placed on the laboratory is small.
Recommendations
As a result of this study and our previous experience with partial rescreening, we can make several recommendations to laboratories who are adopting or currently using a rapid review technique. Firstly, we recommend that a prescreening trial be carried out by screeners in order to measure detection rates. This is essential as (1) it allows one to determine which members of the cytology team should carry out the procedure and (2) it allows the sensitivity of the method to be determined as this is needed to estimate accurately false negative rates. In the present study, the detection rate achieved after encountering 40 abnormals differed little to that achieved after 100 so it would seem reasonable to assess performance after 40. Secondly, adequate records of each screener's output and errors (detected by rapid review, targeted rescreening and full review) should be kept so that false negative rates for screeners and the laboratory may be calculated and monitored. And finally, we would suggest that those undertaking rapid review should achieve a detection rate of around 80%. With this figure as a minimum requirement, a laboratory with a primary screening false negative rate of 20% should be able to reduce this to below the 5% benchmark for reports leaving the laboratory.
